HLTH 2026: Calibrate, Withings study finds wraparound care boosts GLP-1 weight loss by more than 60%

GLP-1 semaglutide injection pen plus a tape measure used to measure a waist circumference are on a bathroom sink
Connected health devices like smart scales will play a growing role in GLP-1 treatment programs and broader chronic disease management, Antoine Pivron, Withings Health Solutions' vice president, said. (cbarnesphotography/GettyImages)

LAS VEGAS—As health plans and employers continue to evaluate the costs and outcomes associated with GLP-1 weight loss drugs, a new study found that wraparound clinical care and behavior change support can make expensive GLP-1 treatments more effective and durable.

A two-year real-world study from Withings Health Solutions and Calibrate Health suggests that pairing GLP-1 medications with Calibrate’s integrated obesity care program produced substantially greater weight loss than GLP-1 treatment alone, and Calibrate members sustained more of their weight loss. 

The study followed 4,961 U.S. adults who began GLP-1s between 2022 and 2024, comparing 3,422 Calibrate members with 1,539 Withings users taking GLP-1s without the program. After adjustment for differences between the groups, Calibrate members lost 17.3% of their starting weight at two years versus 10.7% for the GLP-1-only group, a more than 60% relative difference.

The study was a real-world observational analysis, not a randomized controlled trial. Because Calibrate members chose to join the program, the two groups differed at the start. Before comparing, a statistical adjustment made them comparable on age, sex, race, BMI, health conditions and GLP-1 treatment. Weight was followed over 24 months.

The study findings, shared first with Fierce Healthcare, underscore that GLP-1 treatment may work better when medication is paired with personalized clinical management, behavioral coaching and continuous monitoring, rather than being treated primarily as a prescription benefit, according to Calibrate, a digitally integrated obesity management solution.

The study results also reinforce that obesity should be treated as a disease, another chronic metabolic condition requiring intensive, ongoing support, rather than a medication-only problem, Linda Anegawa, M.D., Calibrate Health’s chief medical advisor, told Fierce Healthcare. 

“With any chronic disease, like hypertension for example, you won’t get as good outcomes if you just hand someone a medication and don’t support them across other pillars of health, like self-monitoring blood pressure, physical activity, and stress reduction. Type 2 diabetes is another good example; you can give high doses of insulin, but medication can’t do the job alone without nutrition education and support,” she said.

“[The study results] make it very clear that treatment [for obesity] shouldn’t stop at just drug coverage,” she added. “As we envision the future, I’d like to see obesity care looking very similar to diabetes care, with insurance covering the full range of necessary services from medication treatment to nutrition education and overall lifestyle support. Obesity is a complex, chronic disease deserving of the same coverage parity as any other."

Treating obesity as such not only prevents health complications and improves quality of life, but it will also lower overall long-term health systems’ costs of care, Anegawa asserted.

Wraparound care widens the weight-loss gap

The advantage of the integrated care program persisted despite weight regain, the study found. While both study groups regained some weight after reaching their lowest point, the Calibrate members remained about 16.6% below their starting weight, according to the study results. The GLP-1-only group reached a best point of 12.6% weight loss and was about 9.2% below baseline at the peak of its rebound.

There was a body-composition benefit as well. In a subgroup of 974 participants followed for body composition, the muscle-to-fat ratio improved 49.3% for Calibrate members versus 39.9% for GLP-1-only users at 18 months, roughly a 9-point difference.

The study data is based on two years of daily weigh-ins from Withings connected scales, analyzed with causal-inference methods. Body composition was followed over 18 months in 520 Calibrate members and 454 Withings users.

The study reinforces the importance of evaluating body composition, rather than weight alone, in obesity treatment, Anegawa said.

“We know that abnormal visceral fat accumulation and dysfunction is what drives most of the metabolic conditions we treat, so if we aren’t equipping members to maximize visceral fat loss and preserve muscle, we can actually end up making people sicker. Losing muscle has severe consequences—it isn’t just scaffolding. Muscle is a critical metabolic organ that regulates energy balance, hormonal signaling, and insulin sensitivity,” she said.

Adding the insights of body composition to Calibrate's clinical and metabolic data allows the company to better monitor trends and adapt care based on quality evidence, she noted.

There are several key factors that make an integrated obesity care program more effective than a medication-only program, Anegawa said.

"Physician-led personalized care that includes medication optimization for each member’s needs, tailored wraparound support, and features that drive continuous engagement—all of which are designed to maximize clinical outcomes," she said.

"Breaking this down, we start with a comprehensive clinical evaluation for each member, vs. other programs which only require a questionnaire for a prescription. This helps us get to know each member’s medical and weight histories in detail. We analyze comprehensive lab data to understand their baseline metabolic profile. This information is then used by our expert clinicians to personalize clinical care from day one," Anegawa said.

Live one-to-one coaching support focuses on four pillars of healthy weight maintenance: nutrition, activity, sleep and mindset shift. Tailored education and anticipatory guidance help members manage side effects and stay on treatment, while connecting members to their personal motivations helps sustain engagement through challenges and supports lasting improvements in metabolic health, according to Calibrate.

Continuous data offers a fuller picture

Calibrate Health has been working with connected health device maker Withings for over five years. The company's members use Withings devices regularly as a required part of the program, according to Anegawa.

"We were already getting body composition data that gave us additional insights into individual members’ health. That data led to additional questions, such as are there significant differences that we can see in aggregate? If so, how large are the differences, and are they changing clinical outcomes? Can we use these data to inform and improve the evolution of our protocols and clinical care? So in asking these types of questions, it became clear to both the Calibrate and Withings teams that we should formalize this into a collaborative study," she noted.

The use of smart devices, specifically Wi-Fi or Bluetooth-connected scales, provides continuous data to help identify weight loss patterns that might not have been apparent through traditional clinical measures, noted Antoine Pivron, vice president of Withings Health Solutions.

"Today, most people on a GLP-1 are monitored through a keyhole. A patient whose primary care doctor prescribes the drug might be weighed a few times a year, and each reading reflects one day: what they ate, the time, the clothes they wore. Between visits, nobody knows whether they plateaued in month three, started regaining in month five, or stopped the drug altogether," he said.

"Specialty programs do better, but many rely on self-reported weights from whatever scale the patient owns. And people tend to stop reporting exactly when things go wrong, which is the moment the care team most needs to know," he added.

Body composition is the biggest blind spot, Pivron asserted. Withings' smart scales track weight and detailed body composition metrics to help identify whether the weight coming off during treatment is fat or muscle.

"In the study we did with Calibrate, two years of data let us see the full shape of the journey: the drop, the low point, and the partial regain that follows. We could also see the quality of the weight loss, not just the quantity. Program members improved their muscle-to-fat balance more, but part of their extra weight loss was muscle. That tells a program exactly where to focus next: protein and strength training," Pivron said.

Withings, a French consumer electronics company, launched its B2B health solutions division in 2019 to meet the growing market around virtual care and remote management in the U.S.

Pivron expects connected health devices like smart scales to play a growing role in GLP-1 treatment programs and broader chronic disease management. 

"A GLP-1 prescription isn’t a care plan. The programs that work combine three things: the drug, the clinical and coaching support around it, and the data that shows whether it’s working. Miss one, and real-world results rarely match what we see in trials," he said.

Body composition will become standard in GLP-1 care, Pivron asserted: "That’s where the clinical definition of obesity is already heading."

Connected devices provide the data layer—continuously tracking weight and body composition, predicting when patients may be veering off course and identifying additional risks such as hypertension.

"But a risk score is not a diagnosis. A notification with no next step just creates anxiety. These signals belong inside a care program with a protocol: confirm with a cuff, see a clinician, treat if needed," he said. "Employers and payers are moving toward paying for outcomes. Connected devices are how a program proves it delivered them."

Better outcomes, but what about costs?

Employers face rising healthcare costs—projected to climb 9.5% next year—and GLP-1 treatments are a major contributor to that cost growth.

The study provides evidence of better outcomes with wraparound care, but it did not evaluate the impact on healthcare spending.

Anegawa contends that improvements in markers associated with high metabolic risk, like Hemoglobin A1c, the liver enzyme ALT and lipids, would point to meaningful cost savings. 

Calibrate data from separate evaluations show substantial improvements in these markers among Calibrate members.

“Among Calibrate members who started the program with diabetes or prediabetes, 80% reached normoglycemic status at one year. Among those with abnormal ALT, 79% shifted to the normal range, and 68% of those with abnormal triglycerides were normal at year one," she said.

Withings' body composition data builds on Calibrate's prior data and gives the company another lens on the whole picture, "suggesting that lower healthcare spend is likely,” Anegawa said.

Greater treatment persistence could also ultimately reduce costs. An integrated approach helps keep members engaged so they stick with treatment and get the full benefit of therapy, she noted.

Along with weight loss and metabolic improvements, Calibrate members also report compelling health and productivity outcomes, Anegawa said. Among members with a high work-related burden at intake, 82% no longer reported it at one year. 

“My favorite evidence of all is that 90% report that Calibrate improved their overall quality of life, and 94% say that their health is better than a year ago - the most clinically meaningful to me overall,” she said.